TEVA News

Latest breaking news and updates for TEVA stock.

Track all markets on TradingView

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Will the FDA approval translate into a significant market‑share gain in the obesity‑treatment segment and how might that reshape competitive dynamics? What pricing advantage does Teva’s generic liraglutide have over the branded Saxenda and other GLP‑1 competitors? How will the launch of the first generic GLP‑1 for weight loss affect Teva’s revenue forecasts and stock valuation?
Drug approval
17 days ago
Read more globenewswire